Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?